Treatment for dry age-related macular degeneration using umbilical cord blood plasma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) to reduce or stabilize the progression of atrophic dry Age-related Macular Degeneration (AMD). Patients aged 65 and older with bilateral dry-AMD will receive CB-PRP injections following different treatment regimens. The study will assess the safety and effectiveness of these injections through advanced retinal imaging techniques and in vitro models. The goal is to observe microanatomical changes in the retina and the response of photoreceptors in the macular region.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥65 years
* Bilateral dry-AMD
* ETDRS-corrected visual acuity between (or equal to) 1/10 and 4/10
* No concomitant ocular pathology (e.g., Glaucoma, amblyopia) or systemic pathology that would result in a BIAS for primary goal assessment
* Signature of informed consent

Exclusion Criteria:

* Age \< 65 years
* Pregnancy
* Previous inflammatory/infectious events involving the eyes
* Eye trauma, diabetes, or disease potentially damaging to the visual system, even in the absence of impairment at the time of intake
* Previous intravitreal treatments.
* Refusal to sign informed consent.

Where it's running

• Fondazione Policlinico Universitario Agostino Gemelli IRCCS
  Rome, Rome, Italy Recruiting

Study contacts

• Study coordinator: Maria Cristina Savastano, MD, PhD
• Email: mariacristina.savastano@policlinicogemelli.it
• Phone: 0630151

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• OCU410 for Geographic Atrophy due to Dry AMD: treatment to help the eye

  A Phase 3 trial tests whether a single subretinal injection of OCU410 can help people 55 and older with geographic atrophy from dry AMD.

  Recruiting Phase 3 Ocugen · Phoenix, Arizona and 2 other locations · NCT07770828

• PathFinder 1.0 detects retinal abnormalities on macular OCT scans

  This study tests PathFinder 1.0's ability to find retinal issues on macular OCT scans in adults.

  Recruiting at 5 sites Carl Zeiss Meditec-Dublin CoCe · Tucson, Arizona and 5 other locations · NCT07680244

• Subretinal CPCB-RPE1 implant for advanced dry AMD with geographic atrophy

  This trial will try a surgical CPCB-RPE1 implant in one eye to see if it is safe and helps people aged 55–90 with advanced dry AMD and geographic atrophy that involves the fovea.

  Recruiting at 5 sites Phase 2 Regenerative Patch Technologies, LLC · Huntington Beach, California and 4 other locations · NCT06557460

• Registry to assess light therapy for dry age-related macular degeneration

  This study is testing if a new light therapy can safely help people with dry age-related macular degeneration see better.

  Recruiting LumiThera, Inc. · Beverly Hills, California and 5 other locations · NCT06351605

• Treatment for dry age-related macular degeneration using umbilical cord blood platelet-rich plasma injections

  This study is testing if injections of umbilical cord blood platelets can help older adults with dry age-related macular degeneration keep their vision from getting worse.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT05706896

• Transplanting stem cells to treat dry age-related macular degeneration

  This study is testing a new stem cell treatment for people with dry age-related macular degeneration to see if it is safe and well-tolerated.

  Recruiting at 3 sites Phase 1/2 Luxa Biotechnology, LLC · Beverly Hills, California and 2 other locations · NCT04627428

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.